NEW YORK ( TheStreet) -- Celgene Corporation (Nasdaq: CELG) hit a new 52-week high Tuesday as it is currently trading at $76.14, above its previous 52-week high of $76.09 with 3.3 million shares traded as of 4 p.m. ET. Average volume has been 3.4 million shares over the past 30 days. Celgene has a market cap of $32.86 billion and is part of the health care sector and drugs industry. Shares are up 11.2% year to date as of the close of trading on Monday. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. The company has a P/E ratio of 26.4, below the average drugs industry P/E ratio of 31.1 and above the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter